| Literature DB >> 34233192 |
Louise Dupraz1, Aurélie Magniez2, Nathalie Rolhion3, Mathias L Richard2, Grégory Da Costa2, Sothea Touch3, Camille Mayeur2, Julien Planchais2, Allison Agus2, Camille Danne2, Chloé Michaudel2, Madeleine Spatz2, François Trottein4, Philippe Langella2, Harry Sokol5, Marie-Laure Michel6.
Abstract
Gut interleukin-17A (IL-17)-producing γδ T cells are tissue-resident cells that are involved in both host defense and regulation of intestinal inflammation. However, factors that regulate their functions are poorly understood. In this study, we find that the gut microbiota represses IL-17 production by cecal γδ T cells. Treatment with vancomycin, a Gram-positive bacterium-targeting antibiotic, leads to decreased production of short-chain fatty acids (SCFAs) by the gut microbiota. Our data reveal that these microbiota-derived metabolites, particularly propionate, reduce IL-17 and IL-22 production by intestinal γδ T cells. Propionate acts directly on γδ T cells to inhibit their production of IL-17 in a histone deacetylase-dependent manner. Moreover, the production of IL-17 by human IL-17-producing γδ T cells from patients with inflammatory bowel disease (IBD) is regulated by propionate. These data contribute to a better understanding of the mechanisms regulating gut γδ T cell functions and offer therapeutic perspectives of these cells.Entities:
Keywords: IL-17; SCFA; T cells; gut; propionate; γδ
Mesh:
Substances:
Year: 2021 PMID: 34233192 DOI: 10.1016/j.celrep.2021.109332
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423